Volume 231, Issue 6

Search all Psychopharmacology articles

March 2014

Autism Spectrum Disorders – An Emerging Area in Psychopharmacology

Issue Editors:

Will Spooren,
Declan Murphy,
Thomas Steckler

19 articles in this issue

Autism spectrum disorders - an emerging area in psychopharmacology
Thomas Steckler
Will Spooren
Declan Murphy
Editorial 31 January 2014 Pages: 977 - 978
Self-injurious behaviour in autistic children: a neuro-developmental theory of social and environmental isolation
Darragh P. Devine
Review 21 September 2013 Pages: 979 - 997
Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study
Yingfen Hsia
Angel Y. S. Wong
Ian C. K. Wong
Original Investigation 05 September 2013 Pages: 999 - 1009
Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care
Macey L. Murray
Yingfen Hsia
Ian C. K. Wong
Original Investigation Open access 17 May 2013 Pages: 1011 - 1021
Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders
Laura C. Politte
Christopher J. McDougle
Review 04 April 2013 Pages: 1023 - 1036
Neurobiology of autism gene products: towards pathogenesis and drug targets
Kristel T. E. Kleijer
Michael J. Schmeisser
J. Peter H. Burbach
Review 14 January 2014 Pages: 1037 - 1062
Using genetic findings in autism for the development of new pharmaceutical compounds
Jacob A. S. Vorstman
Will Spooren
Jan K. Buitelaar
Review 30 November 2013 Pages: 1063 - 1078
The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders
Graham Cocks
Sarah Curran
Jack Price
Theoretical and Methodological Perspectives Open access 10 July 2013 Pages: 1079 - 1088
Human pluripotent stem cell models of autism spectrum disorder: emerging frontiers, opportunities, and challenges towards neuronal networks in a dish
Stefan Aigner
Tobias Heckel
Ravi Jagasia
Review Open access 14 November 2013 Pages: 1089 - 1104
Pharmacological characterisation of ligand- and voltage-gated ion channels expressed in human iPSC-derived forebrain neurons
Jeffrey L. Dage
Ellen M. Colvin
Daniel Ursu
Original Investigation 16 January 2014 Pages: 1105 - 1124
Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives
Martien J. Kas
Jeffrey C. Glennon
Thomas Steckler
Review 19 September 2013 Pages: 1125 - 1146
Advancing the discovery of medications for autism spectrum disorder using new technologies to reveal social brain circuitry in rodents
Martien J. Kas
Meera E. Modi
Daniel G. Smith
Review 13 February 2014 Pages: 1147 - 1165
Neuroimaging Endophenotypes in Animal Models of Autism Spectrum Disorders: Lost or Found in Translation?
Marija M. Petrinovic
Basil Künnecke
Review 14 July 2013 Pages: 1167 - 1189
Lasting neurobehavioral abnormalities in rats after neonatal activation of serotonin 1A and 1B receptors: possible mechanisms for serotonin dysfunction in autistic spectrum disorders
Nidhi Khatri
Kimberly L. Simpson
Ian A. Paul
Original Investigation 24 August 2013 Pages: 1191 - 1200
Biomarkers in autism spectrum disorder: the old and the new
Barbara Ruggeri
Ugis Sarkans
Antonio M. Persico
Review 06 October 2013 Pages: 1201 - 1216
Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development
Andreea S. Pop
Baltazar Gomez-Mancilla
Fabrizio Gasparini
Review 15 November 2013 Pages: 1217 - 1226
Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant
Andreea S. Pop
Josien Levenga
Rob Willemsen
Original Investigation 21 December 2012 Pages: 1227 - 1235
The challenges of clinical trials in fragile X syndrome
Sébastien Jacquemont
Elizabeth Berry-Kravis
Baltazar Gomez-Mancilla
Review Open access 31 October 2013 Pages: 1237 - 1250
A randomized, double-blind, placebo-controlled crossover study of α₄β₂* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder
Aurelija Jucaite
John Öhd
Björn Paulsson
Original Investigation 03 May 2013 Pages: 1251 - 1265

Volume 231, Issue 6

Autism spectrum disorders - an emerging area in psychopharmacology

Self-injurious behaviour in autistic children: a neuro-developmental theory of social and environmental isolation

Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study

Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care

Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders

Neurobiology of autism gene products: towards pathogenesis and drug targets

Using genetic findings in autism for the development of new pharmaceutical compounds

The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders

Human pluripotent stem cell models of autism spectrum disorder: emerging frontiers, opportunities, and challenges towards neuronal networks in a dish

Pharmacological characterisation of ligand- and voltage-gated ion channels expressed in human iPSC-derived forebrain neurons

Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives

Advancing the discovery of medications for autism spectrum disorder using new technologies to reveal social brain circuitry in rodents

Neuroimaging Endophenotypes in Animal Models of Autism Spectrum Disorders: Lost or Found in Translation?

Lasting neurobehavioral abnormalities in rats after neonatal activation of serotonin 1A and 1B receptors: possible mechanisms for serotonin dysfunction in autistic spectrum disorders

Biomarkers in autism spectrum disorder: the old and the new

Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development

Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant

The challenges of clinical trials in fragile X syndrome

A randomized, double-blind, placebo-controlled crossover study of α₄β₂* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder

Navigation